ArticleSaudi medical journal2026
Bridging the Evidence Gap: A Retrospective Lens on Survival and Treatment Patterns in Older Patients With Colorectal Cancer.
Article in Saudi medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To advise evidence-based strategies and healthcare policies to optimize the management of older adults with colorectal cancer (CRC) in the region. Older adults are disproportionately affected by CRC but are underrepresented in clinical trials. Hence, real-world data are crucial in guiding treatment in this population. Methods: We conducted a retrospective cohort study involving patients aged ≥65 years diagnosed with CRC between 2015 and 2021 at King Abdullah Medical City, Makkah, Saudi Arabia. Clinical data, treatment patterns, and survival outcomes were analyzed. Results: Among 256 patients (mean age 74.7; 61.7% male), 75% had an Eastern Cooperative Oncology Group performance status of ≥2, and 31.2% presented with metastatic disease. Curative surgery was performed in 66.4% of patients, and 37.9% received adjuvant chemotherapy. Among patients experiencing metastatic disease, only 36% of patients received first-line therapy, and this proportion declined to 2% by fourth-line therapy. The median overall survival was 42 months, with a 5-year survival rate of 45%. Adjuvant chemotherapy (hazard ratio [HR] = 0.20; Conclusions: Despite functional limitations, older patients benefit from standard therapies. These findings support function-based decision-making and routine integration of geriatric assessments into clinical care to improve outcomes in older patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.